Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jul 4:2019:5692317.
doi: 10.1155/2019/5692317. eCollection 2019.

Novel Agents in Heavily Pretreated Metastatic Gastric Cancer: More Shadows Than Lights

Giandomenico Roviello  1 , Alberto D'Angelo  2 , Raheleh Roudi  3 , Roberto Petrioli  4 , Enrico Mini  1
Affiliations
Review

Novel Agents in Heavily Pretreated Metastatic Gastric Cancer: More Shadows Than Lights

Giandomenico Roviello et al. J Oncol. .

Abstract

Metastatic gastric cancer is still a disease with a poor prognosis. Recently, different novel agents (e.g., apatinib, nivolumab, TAS-102) have demonstrated a survival advantage compared with placebo for patients with heavily pretreated metastatic gastric cancer. Although the possible availability of active agents may be a desirable option in a very poor therapeutic scenario, clinical data from the recent studies with these drugs raise yet controversial issues. The purpose of this review is to briefly summarize the results of these novel drugs focusing on the limitations that bring some shadows on their positive therapeutic results.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Data of median overall survival (OS) of the experimental arm and placebo arm and delta OS difference between OS of the experimental arm and placebo arm.
Figure 2
Figure 2
Data of median progression-free survival (PFS) of the experimental arm and placebo arm and delta PFS difference between PFS of the experimental arm and placebo arm.
Figure 3
Figure 3
Pooled analysis according to previous ramucirumab.
See this image and copyright information in PMC

References

    1. Wagner A. D., Syn N. L., Moehler M., et al. Chemotherapy for advanced gastric cancer. Cochrane Database of Systematic Reviews. 2017;8, article CD004064 - PMC - PubMed
    1. Salati M., Di Emidio K., Tarantino V., Cascinu S. Second-line treatments: moving towards an opportunity to improve survival in advanced gastric cancer? ESMO Open. 2017;2(3, article e000206) - PMC - PubMed
    1. Wilke H., Muro K., van Custem E., et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. The Lancet Oncology. 2014;15(11):1224–1235. doi: 10.1016/s1470-2045(14)70420-6. - DOI - PubMed
    1. Fuchs C. S., Tomasek J., Yong C. J., et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. The Lancet. 2014;383(9911):31–39. doi: 10.1016/S0140-6736(13)61719-5. - DOI - PubMed
    1. Roviello G., Ravelli A., Fiaschi A. I., et al. Apatinib for the treatment of gastric cancer. Expert Review of Gastroenterology & Hepatology. 2016;10(8):887–892. - PubMed

LinkOut - more resources